🚀 VC round data is live in beta, check it out!
IBT Valuation Multiples
Discover revenue and EBITDA valuation multiples for IBT and similar public comparables like Adicet Bio, Synthaverse, Valerio Therapeutics, Orexo and more.
IBT Overview
About IBT
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
Founded
2011
HQ
Employees
10
Website
Sectors
Financials (LTM)
EV
$63M
IBT Financials
IBT reported last 12-month revenue of — and negative EBITDA of ($10M).
In the same LTM period, IBT generated — in gross profit, ($10M) in EBITDA losses, and had net loss of ($8M).
Revenue (LTM)
IBT P&L
In the most recent fiscal year, IBT reported revenue of — and EBITDA of ($7M).
IBT expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($10M) | XXX | ($7M) | XXX | XXX | XXX |
| Net Profit | ($8M) | XXX | ($7M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
IBT Stock Performance
IBT has current market cap of $79M, and enterprise value of $63M.
Market Cap Evolution
IBT's stock price is $5.85.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $63M | $79M | 0.9% | XXX | XXX | XXX | $-0.53 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIBT Valuation Multiples
IBT trades at (6.6x) EV/EBITDA.
IBT Financial Valuation Multiples
As of April 18, 2026, IBT has market cap of $79M and EV of $63M.
Equity research analysts estimate IBT's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
IBT has a P/E ratio of (9.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $79M | XXX | $79M | XXX | XXX | XXX |
| EV (current) | $63M | XXX | $63M | XXX | XXX | XXX |
| EV/EBITDA | (6.6x) | XXX | (8.5x) | XXX | XXX | XXX |
| EV/EBIT | (6.6x) | XXX | (8.4x) | XXX | XXX | XXX |
| P/E | (9.6x) | XXX | (11.1x) | XXX | XXX | XXX |
| EV/FCF | (6.2x) | XXX | (8.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified IBT Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
IBT Margins & Growth Rates
IBT's revenue in the last fiscal year grew by —.
IBT's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.8M for the same period.
IBT Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | (100%) | XXX | 92% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
IBT Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| IBT | XXX | XXX | XXX | XXX | XXX | XXX |
| Adicet Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Synthaverse | XXX | XXX | XXX | XXX | XXX | XXX |
| Valerio Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Orexo | XXX | XXX | XXX | XXX | XXX | XXX |
| Estrella Immunopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
IBT M&A Activity
IBT acquired XXX companies to date.
Last acquisition by IBT was on XXXXXXXX, XXXXX. IBT acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by IBT
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialIBT Investment Activity
IBT invested in XXX companies to date.
IBT made its latest investment on XXXXXXXX, XXXXX. IBT invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by IBT
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout IBT
| When was IBT founded? | IBT was founded in 2011. |
| Where is IBT headquartered? | IBT is headquartered in Sweden. |
| How many employees does IBT have? | As of today, IBT has over 10 employees. |
| Who is the CEO of IBT? | IBT's CEO is Staffan Stromberg. |
| Is IBT publicly listed? | Yes, IBT is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of IBT? | IBT trades under IBT B ticker. |
| When did IBT go public? | IBT went public in 2016. |
| Who are competitors of IBT? | IBT main competitors are Adicet Bio, Synthaverse, Valerio Therapeutics, Orexo. |
| What is the current market cap of IBT? | IBT's current market cap is $79M. |
| Is IBT profitable? | No, IBT is not profitable. |
| What is the current EBITDA of IBT? | IBT has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of IBT? | Current EBITDA multiple of IBT is (6.6x). |
| What is the current FCF of IBT? | IBT's last 12 months FCF is ($10M). |
| What is the current EV/FCF multiple of IBT? | Current FCF multiple of IBT is (6.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.